Rising Stars Outlook 2016 : New Emergence of Potential Tx & Dx Options Could Transform the Current Landscape for Liver Diseases (Nash

SUMMARY

Non-Alcoholic SteatoHepatitis (NASH) is an unmet medical need and is becoming the leading cause of liver transplant. No FDA-approved therapies and a meager diagnosis, it poses a unique challenge in the design of studies for NASH. Therefore, there is a worldwide need for new therapies to treat the global epidemic of NASH and the cost to society will be huge if it is not addressed in the upcoming years! Besides, scarcity of treatment options, there is also an urgent unmet need to develop biomarkers that facilitate the diagnosis, identification of populations at risk, assessment of disease progression or regression, and/or response to treatment. The potential market is gigantic with analysts predicting north of $35bn by 2025!

Browse Detail Report With TOC @ https://marketreportscenter.com/reports/139675/rising

Many small players are currently developing drugs on their own and with such a large unmet need, market potential and disease heterogeneity, we expect many Giants to join this race and thus, we can see more Licensing deals/ M&A activity on the horizon! In light of recent developments in NASH, we have added few in-depth coverage of companies which either target early-stage NASH, late-stage NASH, or large pts pool-NAFLD in our Outlook this year.

Table of Contents

1. Conatus Pharmaceuticals (CNAT)

-

Emricasan: Disease Modifying Potential across the Spectrum of Liver Diseases

- KEY MILESTONES (CNAT)

- 2. Trends in overall population driven by significant improvement in MELD ?15 subgroup

Figure 1

Conatus Pharma

EMRICASAN: DATA FROM PHII, LIVER CIRRHOSIS TRIAL (3-MONTH

- Table 1

Conatus Pharma

PHIIB, ENCORE PROGRAM IN DIFFERENT ETIOLOGIES & STAGES

- Table 2

Conatus Pharma

COMPETITIVE LANDSCAPE (LATE-STAGE PIPELINE) FOR NASH

- Figure 2

Conatus Pharma

EMRICASAN: MEDICAL NEED AND MARKET OPPORTUNITIES

- Figure 3

Conatus Pharma

EMRICASAN: A POTENT INHIBITOR OF APOPTOTIC AND INFLAMMATORY CASPASES

- Figure 4

Conatus Pharma...